Eli Lilly hit $1 trillion market cap on Jan. 9, 2026, driven by strong earnings, drug success, and strategic moves.

The FDA released AI drug development guidelines, with one AI-designed drug now in clinical trials.

A U.S. court blocked Edwards' $945M purchase of JenaValve over antitrust concerns, citing reduced competition in heart valve device markets.

Teva and Royalty Pharma partner to speed up a vitiligo treatment's development.

Healthcare stocks rise in early 2026 due to aging populations and medical innovation.

FDA grants breakthrough status to Ipsen’s drug for unfit acute myeloid leukemia.

A cholera toxin slowed tumor growth in mice by targeting cancer cells and boosting immunity without side effects, offering hope for safer cancer treatments.

Celltrion expands U.S. operations, boosts drug capacity, and advances oncology pipeline with FDA-reviewed candidates.

China finalizes bulk purchase of 440 medical devices, cutting costs and expanding access by May 2026.

A UK man becomes first to receive NHS-funded CAR-T therapy, beating aggressive leukemia.